List of Biotech, Pharmaceutical & Life Sciences companies in Norway - 28

Growing resistance against antibiotics is quickly becoming the greatest threat to human health. The use of antibiotics in food production is partly to blame. With that backdrop, it was a small sensation when ACD Pharma in 2018 got the approval for a phage product that efficiently removes a harmful bacteria and outbreaks of a disease which has antibiotics as its only cure. Bacteriophages, or phages, are the world most numerous organisms. Its only function is to attack and kill their specific target bacteria, and in the process multiply. They are natural predators of bacteria, and Nature’s own biocontrol tools, efficiently ensuring that no single bacterium becomes too dominant in an environment. In other words, bacteriophage-based products do not affect the commensal microflora of the patient or aquaculture farm water, which is a common side-effect of broad-range antibacterials. Our bacteriophage therapy project started in 2011 and has seen promising results of phage therapy against many bacterial pathogens common in aquaculture. Our first approved product, Custus®YRS, contains five hundred thousand billion Yersinia-killing bacteriophages per liter. As these are added in high density to production water or bio-filters an upper limit for the concentration of Yersinia ruckeri that can possibly prevail in the water is quickly established. If the infection pressure is already higher than this limit, it will quickly fall below the limit and prevent the spread of bacteria to healthy fish. We have several other applications in the pipeline and look forward to launching bacteriophage-products in the future.

Aging is the main cause behind most illnesses that eventually kill us. Your chance of dying doubles every 8 years. By the time you turn 80, half of your peers are dead. However, it turns out aging is a biological process, amenable to treatment. Research has demonstrated that we can postpone the onset of age-related disease. Lab mice know this already. Experiments with caloric restriction, senolytics and metabolic inhibitors have extended life and reversed aging - in mice. But how do we know these treatments will work in humans? We can wait and see if patients receiving these new treatments die later. Or see if onset of age-related disease is postponed. But this is slow. It takes many, many years to know for sure if the treatments work. Wouldn’t it be great if we had a faster way? Thanks to the discovery of the epigenetic clock, we can now accurately describe changes to gene regulation caused by aging. By turning this discovery into a blood test, we can measure the exact aging status inside human cells. This will be incredibly useful to researchers involved in aging research. They would know if a treatment works, much earlier than before. So that’s what we’re making: A biomarker for aging which is accurate, affordable and quick.

APIM Therapeutics is a venture capital financed Norwegian biotech company focusing on the development of novel treatments in the fields of oncology and inflammation. Our lead drug, ATX-101, is a first-in-class peptide drug candidate targeting a novel therapeutic intervention point involved in cellular stress defense mechanisms. ATX-101 is currently being tested in a phase I study in patients with advanced solid tumors.

Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on the unique properties of bioactive marine compounds. The company’s pharmaceutical business is developing a novel oral treatment for mild-to-moderate psoriasis, a large global market with significant unmet medical need. Arctic Bioscience will offer convenient and cost-efficient pharmaceutical treatment extracted from a natural raw material (herring roe). The nutraceutical business has proven traction in the premium Omega 3 market with global expansion potential in B2C and B2B channels. To support its long-term growth strategy, Arctic Bioscience is integrating its value chain and planning a state-of-the-art manufacturing facility with a proprietary production process to enable large-scale high-quality production. Based in Ørsta on the West Coast of Norway with access to locally sourced herring roe raw material and led by a team with 30+ years of marine extracts experience, Arctic Bioscience is on a mission to empower healthy lives.

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world. We provide our customers with cold-adapted enzymes from the arctic environment with unique features including heat lability and activity in challenging environments, as well as, customised engineered novel features which can be easily integrated to fuel their innovations. For more information, please visit www.arcticzymes.com

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world. We provide our customers with cold-adapted enzymes from the arctic environment with unique features including heat lability and activity in challenging environments, as well as, customised engineered novel features which can be easily integrated to fuel their innovations. For more information, please visit www.arcticzymes.com

Augere Medical is a commercial stage Norwegian medical device company founded in 2018 and is developing systems based on Artificial Intelligence (AI) to improve polyp detection rates during screening for colorectal cancer. The term "augere" is derived from Latin, meaning "to increase" or "to grow" - hence the green color in our logo. It is the root of several words in English and other languages, including "authority," which signifies the power to promote or bring about growth. Augere’s first product, the PolypAID System, is being developed in cooperation with leading colonoscopists and in close cooperation with the research group at Simula. The PolypAID System analyses the real-time video stream during colonoscopy screening and supports the physicians in making the right decision during the screening process. We pledge to implement transparent AI to physicians and patients. These are our values, mission, vision, and tagline statements: OUR VALUES Quality We are delivering high quality products through focus on details and by meeting customer expectations.   Innovation We are in the forefront of the technology development by embracing continuous improvements and investing in our employees.   Care We care about the patients who will benefit from our technologies and put real heart into our promises to our investors and customers.   Agility We move fast and are willing to adapt to changing market conditions regardless of the size of the company.   Delivering results We have grit to deliver results by defining clear objectives and by meeting deadlines. MISSION Making lives better   VISION Augere will, through partnerships with the world's leading clinical and technical research environments, develop a platform for AI-based systems that improve the detection rate and characterization of cancer and precancerous abnormalities and thereby reduce the burden on patients and the cost of cancer treatment   TAGLINE Confidence in outcomes (TM)

Bionor Holding is a privately held biopharmaceutical company focused on advancing its proprietary therapeutic vaccines toward HIV cure.

Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

CardioMech is a medical device company that is developing a transfemoral, transseptally delivered mitral valve chordal repair technology to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or other structural abnormalities.

Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.

Curida is a Contract Development and Manufacturing Organization for Pharmaceuticals, based in Norway. We are building on more than 40 years of experience and offer premium quality manufacturing to international pharma companies. Curida has core competency on sterile and aseptic manufacturing of liquid pharmaceuticals. Our core technologies are blow-fill-seal (BFS) and nasal spray. We work with companies ranging from small biotech to Big Pharma. We have a lean and flexible organization that will, enabling a strong partnership with our customers.

Cytovation is a clinical-stage immuno-oncology biotech focused on the development of CyPep-1, a first-in-class tumor membrane immunotherapy for the treatment of various diseases, including benign tumors and malignant cancers.

Genetic Analysis AS (GA) is positioned to become a world leader within the field of molecular in-vitro diagnostics of diseases related to gut imbalances. Based on the patented DNA-based GA-map® platform technology, profiles of patient’s gut microbiota is quickly generated and can be related to various health conditions. Our first product, the GA-map® Dysbiosis Test helps Gastroenterologists to measure and monitor gut microbiota status in patients with Irritable Bowel Syndrome (IBS). This is the first dysbiosis test which is commercially available, standardised, CE-marked and clinically validated (50 clinical trials + 30 publications). Further clinical applications for the tests are in areas such as diagnosis, disease severity course, treatment prediction and monitoring within both IBS (irritable bowel syndrome) and IBD (inflammatory bowel disease) where the need of clinical data and validation is required. GA is thus very active in these fields. Other areas of interest are metabolic disease including diabetes type 2.

Pathogenomix Ripseq sequence-based analysis reduces the time needed to identify infectious pathogens, in pure- or poly-microbial samples, by up to 90% - and provides answers where other methods fail. Use any sequencing technology you want - Sanger or NGS - Ripseq is platform agnostic. Combined with Ripseq DB, this is complete SaaS diagnostic solution, able to identify pathogens more accurately, faster and at lower cost than current methods.

High quality nanoparticle-based solutions for life science, diagnostic and aquaculture purposes: We develop and manufacture products within nucleic acid extraction and sample preparation. We serve customers from hospitals, aquaculture and fish health monitoring as well as academic institutions. Our products simplifies and shorten the sample preparation time with up to 50%!

Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lead compound LTX-315 provides access to antigens by using the patient’s own tumor as source of antigens and turns cold tumors hot. Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.

Navamedic is a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers. Our product portfolio consists of prescription and OTC pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like UK and Greece. Our headquarter is in Oslo, Norway and we are listed on the Oslo Stock Exchange (ticker: NAVA). We are about 30 highly qualified employees with strong competence in regulatory affairs, quality assurance, reimbursement, marketing and sales and thus a full-service provider securing market access through our local competence.

We are a leading technology platform that unlocks unlimited possibilities for the future of medicine through our intelligent modular design and tailored hyper targeting.

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers.

PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities. The company’s lead programme fimaVACC aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAC programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For further information, please visit: www.pcibiotech.com Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo PCI Biotech was established 2000 and is since June 2008 listed on the Oslo Børs. The company is headquartered in Oslo, Norway.

About Photocure Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com On this account Photocure posts about uro-oncology and company activity. All information presented on this account is for informational purposes only and is not intended as a substitute for informed medical advice or recommendations from healthcare professionals. Please consult a healthcare professional for more information about your condition and medicinal products.

Regenics AS is a private Norwegian biotechnology company based in Oslo. Regenics develops novel wound care technologies, based on sustainable marine sources.

Thor Medical's primary market is to supply alpha emitters to suppliers and developers of innovative drugs targeting indications with high unmet medical needs, including any medical products and equipment. Going forward, the main business focus will be to refine the production technology, secure customer qualification and commitments, mature the manufacturing concept, and secure regulatory approvals and permits for industrialization.

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

Vectron Biosolutions develops protein production processes for that leverage their proprietary expression technologies and experience to engineer bespoke bacterial strains. The strains result in maximal titers of biologically active protein. After a project, the strainsare transferred to the customer for use under a license agreement, together with all required documentation and protocols.

Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com